News
Early-stage financing rounds are on track to hit their lowest dollar value in years as funders continue to eschew risky investments, experts told BioSpace.
FEATURED STORIES
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
Molecular glue degraders are gaining traction in the clinic as well as funding from Big Pharma, with their potential to treat previously “undruggable” cancers and immunological diseases. Here are five clinical programs worth keeping an eye on.
Last month, the FDA launched TrialBlazer, intended to streamline the IND path and bring early clinical trials and medical innovation home to the U.S. It’s a start, but new agency leadership must see it through.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
This year’s AACR Annual Meeting is coming to a close, and there has been a wealth of information and data presented. One topic of discussion stood out—mutations.
Companies working on cell therapies got most of the funding in the life sciences venture capital world this week. For that and more, continue reading.
As the American Association of Cancer Research (AACR) Annual Meeting wraps up, there were some surprising and exciting research news and presentations.
Reports that myopericarditis may be a side effect of COVID-19 vaccination are downplayed by a recently published study that suggests there might not be a correlation.
As the world speculates the potential impact of the novel COVID-19 variant omicron XE and subvariant BA.2, research continues to shed light on the impact and future of the pandemic.
With Spring comes new beginnings, and companies within the biopharmaceutical industry are blossoming with fresh ventures. Here are some of them:
9 Meters Biopharma has received notice from the U.S. Patent and Trademark Office (USPTO) allowing its patent for therapeutic NM-136 to treat hyperphagia (extreme hunger) and obesity.
The FDA has sprung into action, cracking down on the illegal sales of Adderall, as well as on CBD companies making claims their products are effective treatments or cures for COVID-19.
GSK is acquiring Sierra Oncology for $1.9 billion in a deal expected to help both companies take a major step in developing a treatment for rare types of cancer.